IDRA-21
Cognition, Learning
No human pharmacokinetic data published. Preclinical work only.
In short
- A benzothiadiazine ampakine studied in rodents and non-human primates; no human trial has been conducted.
- Attenuates AMPA receptor desensitisation, which is a different and cruder mechanism than TAK-653's agonist-dependent modulation.
- The ampakine class carries a genuine excitotoxicity concern, and IDRA-21 has none of the design features intended to mitigate it.
- Chemically related to diazoxide and to the diuretic thiazides, though its activity is distinct.
- Research compound only.
Structure
How it works
IDRA-21 slows the desensitisation of AMPA receptors, prolonging the response to glutamate. This increases excitatory signalling and, in animal models, enhances long-term potentiation.
The important contrast is with TAK-653, which was specifically engineered for agonist-dependent activity so it only amplifies signalling where glutamate is already acting. IDRA-21 has no such constraint — it makes AMPA receptors more responsive generally, which is precisely the property that made the earlier ampakine class concerning.
Excessive AMPA activation increases calcium influx, and sustained excessive calcium influx is the mechanism of excitotoxic neuronal injury.
What the research shows
Rodent and non-human primate studies reported improved performance on delayed match-to-sample and learning tasks, with effects reported to outlast the compound's presence.
No human study of any kind has been published.
Reports of cognitive effects in people are anecdotal.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Rat and primate — cognitive task studies | Low milligram-per-kilogram ranges depending on model | oral or intraperitoneal | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported, usually infrequently | 10–30 mg, not daily | oral |
No published human pharmacokinetic study establishes a dose, interval, or duration for this compound. Community figures below have no trial behind them and are reports of practice, not evidence. No toxicology study has been published. For a compound whose class-defining risk is excitotoxicity and seizure threshold, the absence of any human safety work is the central fact rather than a footnote.
Handling and storage
Oral, as powder or capsules from research-chemical vendors. Infrequent use is the commonly described pattern, generally reasoned from the excitotoxicity concern rather than from evidence.
No route, timing, or duration has been established in humans.
Side effects
No human safety data exists, and no toxicology has been published.
The specific class concern is reduced seizure threshold and excitotoxicity. Older ampakines were limited in development by exactly this, and IDRA-21 lacks the agonist-dependence that later compounds were designed around.
Anyone with a seizure history, or taking anything that lowers seizure threshold, is in the group where this concern is most concrete.
Combinations
No interaction data. Combining with anything else affecting glutamatergic signalling or seizure threshold compounds an already uncharacterised risk in the same direction.
Research status
Preclinical only, largely from the 1990s, including work at the National Institute on Drug Abuse. Never entered human trials.
The ampakine field has since moved toward agonist-dependent modulators like TAK-653 precisely because of the concerns this generation raised.
Legal status
Not approved anywhere. Sold for research use only. Not scheduled in most jurisdictions, which reflects absence of assessment.
WADA status
Not specifically named on the Prohibited List. Falls under WADA class S0, which prohibits any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. Treat it as prohibited in sport.
Conclusion
IDRA-21 is an early-generation ampakine that the field largely moved past, and it never reached human study.
If you are interested in AMPA modulation, TAK-653 has human pharmacokinetics, a Phase 1 safety file, and a mechanism specifically designed to avoid the risk that this compound carries unmitigated.
Sources
Track your own IDRA-21 protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.